NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. Vertex is best known for its ...

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The new 10-year co-branded card deal with Citi, effective in 2026, is expected to boost cash remuneration by ~10% annually, ...